Keryx Biopharma (KERX) Misses Q3 EPS by 2c

November 7, 2017 7:04 AM EST

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $15 million versus the consensus estimate of $18.04 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings